Baicalin reduces the severity of experimental autoimmune encephalomyelitis

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 7, 2007, Pages 1003-1010

  Zeng, Y ^a   Song, C ^a   Ding, X ^a   Ji, X ^a   Yi, L ^b   Zhu, K ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Baicalin; Experimental autoimmune encephalomyelitis; IFN ; IL 4; Neurologic score

Indexed keywords

BAICALIN; GAMMA INTERFERON; INTERLEUKIN 4; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; IMMUNIZATION; IN VITRO STUDY; INCIDENCE; INGUINAL LYMPH NODE; MONONUCLEAR CELL; MOUSE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NONHUMAN;

MUS; SCUTELLARIA BAICALENSIS; VASCELLUM;

EID: 34547787630     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006005000115     Document Type: Article

References (25)

1. Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, et al. Risk factors of multiple sclerosis: a case-control study. Neurol Sci 2003; 24: 242-247.
2. Taira Z, Yabe K, Hamaguchi Y. Hirayama K, Kishimoto M, Ishida S, et al. Effects of Sho-saiko-to extract and its componenets, Baicalin, baicalein, glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats. Food Chem Toxicol 2004; 42: 803-807.
3. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-160.
4. Ohta Y, Nishida K, Sasaki E, Kongo M, Hayashi T, Nagata M, et al. Comparative study of oral and parenteral administration of Sho-saiko-to (xiao-chaihu-tang) extract on D-galactosamine-induced liver injury in rats. Am J Chin Med 1997; 25: 333-342.
5. Lo YC, Lin YL, Yu KL, Lai YH, Wu YC, Ann LM, et al. San-Huang-Xie-Yin-Tang attenuates inflammatory responses in lipopolysaccharide-exposed rat lungs. J Ethnopharmacol 2005; 101: 68-74.
6. Krakauer T, Li BQ, Young HA. The flavonoid baicalin inhibits super-antigen-induced inflammatory cytokines and chemokines. FEBS Lett 2001; 500: 52-55.
7. De Rosa V, Procaccini C, La Cava A, Chieffi P, Nicoletti GF, Fontana S, et al. Leptin neutralization interferes with pathogenic T cell auto-reactivity in autoimmune encephalomyelitis. J Clin Invest 2006; 116: 447-455.
8. Stosic-Grujicic S, Savic-Radojevic A, Maksimovic-Ivanic D, Markovic M, Bumbasirevic V, Ramic Z, et al. Down-regulation of experimental allergic encephalomyelitis in DA rats by tiazofurin. J Neuroimmunol 2002; 130: 66-77.
9. Whitham RH, Bourdette DN, Hashim GA, Herndon RM, Ilg RC, Vandenbark AA, et al. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J Immunol 1991; 146: 101-107.
10. Peng L, Wang B, Ren P. Reduction of MTT by flavonoids in the absence of cells. Colloids Surf B Biointerfaces 2005; 45: 108-111.
11. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-38.
12. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981; 11: 195-199.
13. Kennedy MK, Tan LJ, Dal Canto MC, Tuohy VK, Lu ZJ, Trotter JL, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990; 144: 909-915.
14. McRae BL, Kennedy MK, Tan LJ, Dal Oanto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992; 38: 229-240.
15. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acts Neurol Scand 1988; 78: 318-323.
16. Waldor MK, Sriram S, Hardy R, Herzenberg LA, Herzenberg LA, Lanier L, et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 1985; 227: 415-417.
17. McDonald AH, Swanborg RH. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol 1988; 140: 1132-1138.
18. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Ecp Med 1994; 180: 1961-1966.
19. Miller A, al-Sabbagh A, Santos LM, Das MP, Weiner HL. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J Immunol 1993; 151: 7307-7315.
20. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240.
21. Juedes AE, Ruddle NH. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol 2001; 166: 5168-5175.
22. 2 induced liver injury. Eur J Pharmacol 2006; 536: 192-199.
23. Huang Y, Tsang SY, Yao X, Chen, ZY. Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 177-184.
24. Shen YC, Chiou WF, Chou YC, Chen CF. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol 2003; 465: 171-181.
25. Li BQ, Fu T, Gong WH, Dunlop N, Kung H, Yon Y, et al. The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 2000; 49: 295-306.